Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613838 | 0.77 | ADORA2A (0.45) | PDK1PDK2KDM4EALDH1A1MAPT | |
| SCHEMBL30480710 | 0.77 | ADORA2A (0.45) | PDK1PDK2KDM4EALDH1A1MAPT | |
| SCHEMBL15902309 | 0.73 | ALDH1A1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL23872146 | 0.72 | PDK1 (0.43) | PDK1PDK2KDM4EALDH1A1MAPT | |
| SCHEMBL29324350 | 0.72 | PDK1 (0.43) | PDK1PDK2KDM4EALDH1A1MAPT | |
| SCHEMBL29324204 | 0.71 | PDK1 (0.36) | PDK1PDK2KDM4E | |
| Lithium SCHEMBL31337094 | 0.71 | PDK1 (0.43) | PDK1PDK2KDM4EALDH1A1MAPT | |
| SCHEMBL15902179 | 0.70 | ALDH1A1 (0.51) | KDM4EALDH1A1 | |
| SCHEMBL1163903 | 0.70 | PDK1 (0.31) | PDK1PDK2 | |
| Lithium Ion SCHEMBL23858712 | 0.70 | PDK1 (0.42) | PDK1PDK2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | PDK1 704/4885PDK2 1831/4885ERN1 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.